Meropenem is indicated for the treatment of the following infections caused by susceptible bacteria:

• Intra-abdominal infections
• Skin and skin structure infections
• Bacterial meningitis

Abdominal Infection

Skin Infection

Meningitis

• For complicated skin and skin structure infections (cSSSI) in adult patients, administer 500 mg intravenously every 8 hours through infusion over 15 to 30 minutes. In cases where Pseudomonas aeruginosa is the causative agent, a recommended dose of 1 gram every 8 hours is advised.
• For intra-abdominal infections in adult patients, administer 1 gram intravenously every 8 hours through infusion over 15 to 30 minutes.
• For adult patients, a bolus injection of 1 gram every 8 hours can be administered intravenously over 3 to 5 minutes, using an injection volume ranging from 5 mL to 20 mL.
• It is imperative to adjust the dosage for adult patients with renal impairment, necessitating a reduction in the prescribed amount.

Most common adverse reactions (2% or less) are:

• headache
• nausea
• constipation
• diarrhea
• anemia
• vomiting
• rash

Headache

Nausea

Constipation

Rash

• Serious and, at times, fatal hypersensitivity (anaphylactic) reactions have been documented in patients undergoing treatment with β-lactams.
• During the course of treatment, seizures and other adverse central nervous system (CNS) events have been reported.
• The co-administration of MERREM IV with valproic acid or divalproex sodium diminishes the serum concentration of valproic acid, potentially elevating the risk of breakthrough seizures.
• Cases of Clostridium difficile-associated diarrhea, varying from mild diarrhea to fatal colitis, have been reported. Vigilance and assessment are recommended if diarrhea occurs.
• Thrombocytopenia has been observed in patients with renal dysfunction.